[SIZE=4]Tübingen researchers achieve protection of up to 100 percent using fully viable malaria parasites[/SIZE]
University of Tübingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.
The Tübingen study involved 67 healthy adult test persons, none of whom had previously had malaria. The best immune response was shown in a group of nine test persons who received the highest dose of the vaccine three times at four-week intervals. At the end of the trial, all nine of these individuals had 100 percent protection from the disease.
The next step is to further test the vaccine’s effectiveness over several years in a clinical study in Gabon funded by DZIF.